Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 14/20 | 0.50 |
| ▸ | CCKAR | P32238 | 9/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20098199 | 0.94 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL20098440 | 0.90 | CCKBR (0.57) | CCKBRCCKAR | |
| SCHEMBL20098248 | 0.88 | CCKBR (0.59) | CCKBRCCKAR | |
| SCHEMBL24612007 | 0.81 | CCKBR (0.45) | CCKBRCCKAR | |
| SCHEMBL20098042 | 0.76 | CCKBR (0.54) | CCKBRCCKAR | |
| SCHEMBL21755181 | 0.76 | CCKBR (0.54) | CCKBRCCKAR | |
| SCHEMBL21180055 | 0.75 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL20098169 | 0.75 | CCKBR (0.53) | CCKBRCCKAR | |
| SCHEMBL15402466 | 0.75 | CCKBR (0.62) | CCKBRCCKAR | |
| SCHEMBL20098322 | 0.74 | CCKBR (0.60) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CCKAR 989/4885GABRA1 2/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | CCKBR 3869/4885CCKAR 4257/4885GABRA1 2263/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CCKAR 989/4885GABRA1 2/4885 |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | CCKBR 509/4885CCKAR 989/4885GABRA1 2/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | CCKBR 3869/4885CCKAR 4257/4885GABRA1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.